S-cerevisiae has three pathways for DNA interstrand crosslink repair

被引:88
|
作者
Grossmann, KF [1 ]
Ward, AM [1 ]
Matkovic, ME [1 ]
Folias, AE [1 ]
Moses, RE [1 ]
机构
[1] Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA
来源
MUTATION RESEARCH-DNA REPAIR | 2001年 / 487卷 / 3-4期
关键词
DNA repair; cisplatin; psoralen; DNA interstrand crosslinks; angelicin;
D O I
10.1016/S0921-8777(01)00106-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Yeast mutants, snm1 (pso2-1), rev3 (pso1-1), and rad51, which display significant sensitivity to interstrand crosslinks (ICLs) have low relative sensitivity to other DNA damaging agents. SNM1, REV3, and RAD51 were disrupted in the same haploid strain, singly and in combination. The double mutants, snm1 Delta rev3 Delta, snm1 Delta rad51 Delta and rev3 Delta rad51 Delta were all more sensitive to ICLs than any of the single mutants, indicating that they are in separate epistasis groups for survival. A triple mutant displayed greater sensitivity to ICLs than any of the double mutants, with one ICL per genome being lethal. Therefore, Saccharomyces cerevisiae appears to have three separate ICL repair pathways, but no more. S-phase delay was not observed after ICL damage introduced by cisplatin (CDDP) or 8-methoxypsoralen (8-MOP) during the G1-phase, in any of the above mutants, or in an isogenic rad14 Delta mutant deficient in nucleotide excision repair. However. the psoralen analog angelicin (monoadduct damage) induced a significant S-phase delay in the rad14 Delta mutant. Thus, normal S-phase in the presence of ICLs does not seem to be due to rapid excision repair. The results also indicate that monoadduct formation by CDDP or 8-MOP at the doses used is not sufficient to delay S-phase in the rad14 Delta mutant. While the sensitivity of a rev3 Delta mutant indicates Pol zeta is needed for optimal ICL repair, isogenic cells deficient in Pol eta (rad30 Delta cells) were not significantly more sensitive to ICL agents than wild-type cells, and have no S-phase delay. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:73 / 83
页数:11
相关论文
共 50 条
  • [1] DNA interstrand crosslink repair and cancer
    Andrew J. Deans
    Stephen C. West
    Nature Reviews Cancer, 2011, 11 : 467 - 480
  • [2] DNA interstrand crosslink repair and cancer
    Deans, Andrew J.
    West, Stephen C.
    NATURE REVIEWS CANCER, 2011, 11 (07) : 467 - 480
  • [3] Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
    Andreassen, Paul R.
    Ren, Keqin
    CURRENT CANCER DRUG TARGETS, 2009, 9 (01) : 101 - 117
  • [4] Defining the pathways involved in the initiation and resolution steps of DNA interstrand crosslink repair
    McHugh, PJ
    Hartley, JA
    BRITISH JOURNAL OF CANCER, 2000, 83 : 63 - 63
  • [5] A new varietal of DNA interstrand crosslink repair
    Ravindra Amunugama
    Johannes C. Walter
    Cell Research, 2020, 30 : 459 - 460
  • [6] Molecular Mechanism Of DNA Interstrand Crosslink Repair
    Smogorzewska, Agata
    Kottemann, Molly
    Conti, Brooke
    Thongthip, Supawat
    Rickman, Kimberly
    Lach, Frank
    FASEB JOURNAL, 2016, 30
  • [7] DNA Interstrand Crosslink Repair in Mammalian Cells
    Mccabe, Kevin M.
    Olson, Susan B.
    Moses, Robb E.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2009, 220 (03) : 569 - 573
  • [8] A new varietal of DNA interstrand crosslink repair
    Amunugama, Ravindra
    Walter, Johannes C.
    CELL RESEARCH, 2020, 30 (06) : 459 - 460
  • [9] Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways
    Bilardi, R. A.
    Kimura, K. -I.
    Phillips, D. R.
    Cutts, S. M.
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (09) : 1241 - 1250
  • [10] Translesion DNA Synthesis Polymerases in DNA Interstrand Crosslink Repair
    Ho, Vinh
    Schaerer, Orlando D.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2010, 51 (06) : 552 - 566